Sirtris Pharmaceuticals Presents Results of Studies of SIRT1 Activators at 6th Annual Metabolic Diseases Drug Discovery and Deve
18 July 2007 - 2:00AM
Business Wire
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs
to treat diseases of aging, announced today that it presented data
from pre-clinical and Phase 1a studies at the 6th Annual Metabolic
Diseases Drug Discovery and Development World Summit in San Diego,
California on July 17, 2007. As previously announced, Jill Milne,
Ph.D., Senior Director of Biology at Sirtris, delivered a keynote
address �SIRT1 Activation: A Novel Mechanism for Treating Type 2
Diabetes.� Dr. Milne presented data which showed that SRT501,
Sirtris' proprietary formulation of resveratrol, reduces glucose
and improves insulin sensitivity in multiple pre-clinical models of
Type 2 Diabetes. Dr. Milne also presented pharmacokinetic (PK) data
from a Phase 1a study conducted by Sirtris in which healthy
volunteers who were dosed with SRT501 had an improved exposure as
compared with other published studies. Both the area under the
curve concentrations (AUC) as well as the maximal concentrations
(Cmax) were shown to be improved with SRT501 as compared with
literature values for resveratrol. SRT501 is currently being tested
in a Phase 1b study in patients with Type 2 Diabetes. Furthermore,
Dr. Milne presented data with certain Sirtris proprietary novel
chemical SIRT1 activators, structurally unrelated to resveratrol,
which were shown to reduce glucose, improve insulin sensitivity,
improve glucose tolerance, and increase the number and function of
mitochondria in multiple pre-clinical models of Type 2 Diabetes. In
addition, studies in a pre-clinical model demonstrate improved
insulin sensitivity in muscle, liver, and fat cells. �Sirtris
scientists continue to make significant progress in the development
of SIRT1 activators for diseases of aging such as Type 2 Diabetes.
Indeed, the new data presented today further extend Sirtris�
scientific leadership in advancing sirtuin modulators as a new
class of innovative therapeutics,� said Christoph Westphal, M.D.,
Ph.D., Chief Executive Officer of Sirtris. About Sirtris
Pharmaceuticals Sirtris Pharmaceuticals is a biopharmaceutical
company focused on discovering and developing proprietary, orally
available, small molecule drugs with the potential to treat
diseases associated with aging, including metabolic diseases such
as Type 2 Diabetes. Our drug candidates are designed to mimic
certain beneficial health effects of calorie restriction, without
requiring a change in eating habits, by activation of sirtuins, a
recently discovered class of enzymes that control the aging
process. The company's headquarters are in Cambridge,
Massachusetts. This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements include, but are not limited
to, the progress of pre-clinical and clinical studies of SIRT1
activators, the results of pre-clinical studies as compared with
other published studies, Sirtris� position in the sirtuin field,
and the potential for sirtuin modulators to receive regulatory
approval. These forward-looking statements about future
expectations, plans and prospects of Sirtris Pharmaceuticals
involve significant risks, uncertainties and assumptions, including
risks related to the lack of results that would provide a basis for
predicting whether any of the Company�s product candidates will be
safe or effective, or receive regulatory approval, the possibility
that results of pre-clinical studies are not necessarily predictive
of clinical trial results, the Company's potential inability to
initiate and complete pre-clinical studies and clinical trials for
its product candidates, the fact that none of the Company's product
candidates has received regulatory approvals, the potential
inability of the�Company to gain market acceptance of the Company's
product candidates, and those other risks factors�that can be found
in the�Company's filings with the Securities and Exchange
Commission. Actual results may differ materially from those Sirtris
Pharmaceuticals contemplated by these forward-looking statements.
Sirtris Pharmaceuticals does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release.
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Sierra Natl BK Tehachapi Calif (MM) (NASDAQ): 0 recent articles
More Sirtris Pharmaceuticals, Inc. News Articles